AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Protective role of rosmarinic acid on amyloid beta 42-induced echoic memory decline: Implication of oxidative stress and cholinergic impairment

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1841579> since 2022-02-22T23:13:15Z

Published version:

DOI:10.1016/j.neuint.2018.04.008

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

Manuscript Number: NSC-18-98

Title: Protective role of rosmarinic acid on amyloid beta 42-induced
echoic memory decline: implication of oxidative stress and cholinergic
impairment

Article Type: Research Paper

Section/Category: Disease-Oriented Neuroscience

Keywords: Key words: Amyloid β , Rosmarinic acid, Lipid peroxidation,
Antioxidant system, Cholinergic system, Auditory event related potential.

Corresponding Author: Professor Piraye Yargicoglu, PhD

Corresponding Author's Institution: Akdeniz Univ, Faculty of Medicine

First Author: Deniz Kantar Gok

Order of Authors: Deniz Kantar Gok; Enis Hidisoglu; Guzide Ayse Ocak;
Hakan Er; Alev Duygu Acun; Piraye Yargicoglu, PhD

Abstract: Abstract

In the present study, we examined whether rosmarinic acid (RA) reverses amyloid β (A β) induced reductions in antioxidant defense, lipid peroxidation, cholinergic damage as well as the central auditory deficits. For this purpose, Wistar rats were randomly divided into four groups; Sham(S), Sham+RA (SR), A β 42 peptide (A β) and A β 42 peptide+RA (A β R) groups. Rat model of Alzheimer was established by bilateral injection of A β 42 peptide (2,2 nmol/10 μ l) into the lateral ventricles. RA (50mg/kg, daily) was administered orally by gavage for 14 days after intracerebroventricular injection. At the end of the experimental period, we recorded the auditory event related potentials (AERPs) and mismatch negativity (MMN) response to assess auditory functions followed by histological and biochemical analysis. A β 42 injection led to a significant increase in the levels of thiobarbituric acid reactive substances (TBARS) and 4-Hydroxy-2-nonenal (4-HNE) but decreased the activity of antioxidant enzymes (SOD, CAT, GSH-Px) and glutathione levels. Moreover, A β 42 injection resulted in a reduction in the acetylcholine content and acetylcholine esterase activity. RA treatment prevented the observed alterations in the A β R group. Furthermore, RA attenuated the increased A β staining and astrocyte activation. We also found that A β 42 injection decreased the MMN response and theta power/coherence of AERPs, suggesting an impairing effect on auditory discrimination and echoic memory processes. RA treatment reversed the A β 42 related alterations in AERP parameters. In conclusion, our study demonstrates that RA prevented A β -induced antioxidant-oxidant imbalance and cholinergic damage, which may contribute to the improvement of neural network dynamics of auditory processes in this rat model.

Suggested Reviewers: Xue-Jun Sun

Department of Diving Medicine, Faculty of Naval Medicine, Second Military
Medical University, Shanghai, 200433, PR China
sunxjk@hotmail.com

Marina R. Picciotto
Program in Cellular Neuroscience, Neurodegeneration and Repair Yale
University School of Medicine
marina.picciotto@yale.edu

John M. Olichney
Center for Mind and Brain
jmolichney@ucdavis.edu

Fernando Pena-Ortega
Instituto de Neurobiología
jfpena@unam.mx

Opposed Reviewers:

AKDENİZ UNIVERSITY MEDICAL SCHOOL
Department of Biophysics

Dear Sir/Madam

Enclosed please find the revised paper on the subject of “Protective role of rosmarinic acid on amyloid beta 42-induced echoic memory decline: implication of oxidative stress and cholinergic impairment” to be published in the Journal of “Neuroscience”. I certainly hope, that the paper would satisfy all the requirements for the Journal in order to be published. I have read and have abided by the statement of ethical standards for manuscripts submitted to Neuroscience. We believed that this is an original work as far as the research concern never the less. All authors have approved this manuscript to be published in the “Neuroscience”. I have read and have abided by the statement of ethical standards for manuscripts submitted to Neuroscience.

In any case, if a question arises on the paper, please do not hesitate to contact me as soon as possible.

Thank you for your consideration.

Sincerely,

Piraye Yargicoglu, PhD,

Professor and Chair of Department of Biophysics,

Akdeniz University Faculty of Medicine,

07070 Antalya, Turkey.

Phone: 90-242-2496906

Fax: 90-242-227 44 82

E-mail: pakkiraz@akdeniz.edu.tr

Highlights

- Aβ42 affects antioxidant-oxidant balance and cholinergic system.
- Aβ42 causes deficit in network dynamics of auditory system.
- Rosmarinic acid reverses the Aβ42 induced alterations in auditory functions.
- Cholinergic enhancement via rosmarinic acid might be useful in AD.
- Rosmarinic acid might be efficient in AD treatment with its multiple bioactivities.

**Protective role of rosmarinic acid on amyloid beta 42-induced echoic memory decline:
implication of oxidative stress and cholinergic impairment**

**Deniz Kantar Gok^a, Enis Hidisoglu^a, Guzide Ayse Ocak^b, Hakan Er^a, Alev Duygu Acun^a,
Piraye Yargicoglu^{a*}**

^aDepartment of Biophysics, Faculty of Medicine, Akdeniz University, Arapsuyu, 07070 Antalya /
TURKEY

^bDepartment of Pathology, Faculty of Medicine, Akdeniz University, Arapsuyu, 07070 Antalya /
TURKEY

Correspondence Address: Piraye Yargicoglu, Department of Biophysics, Faculty of Medicine,
Akdeniz University, Arapsuyu, 07070 Antalya / TURKEY

Telephone: Work: 0 090-242-2496906
Fax: 0 090-242-2274495
E-Mail: pakkiraz@akdeniz.edu.tr

Abstract

In the present study, we examined whether rosmarinic acid (RA) reverses amyloid β ($A\beta$) induced reductions in antioxidant defense, lipid peroxidation, cholinergic damage as well as the central auditory deficits. For this purpose, Wistar rats were randomly divided into four groups; Sham(S), Sham+RA (SR), $A\beta$ 42 peptide ($A\beta$) and $A\beta$ 42 peptide+RA ($A\beta$ R) groups. Rat model of Alzheimer was established by bilateral injection of $A\beta$ 42 peptide (2,2 nmol/10 μ l) into the lateral ventricles. RA (50mg/kg, daily) was administered orally by gavage for 14 days after intracerebroventricular injection. At the end of the experimental period, we recorded the auditory event related potentials (AERPs) and mismatch negativity (MMN) response to assess auditory functions followed by histological and biochemical analysis. $A\beta$ 42 injection led to a significant increase in the levels of thiobarbituric acid reactive substances (TBARS) and 4-Hydroxy-2-nonenal (4-HNE) but decreased the activity of antioxidant enzymes (SOD, CAT, GSH-Px) and glutathione levels. Moreover, $A\beta$ 42 injection resulted in a reduction in the acetylcholine content and acetylcholine esterase activity. RA treatment prevented the observed alterations in the $A\beta$ R group. Furthermore, RA attenuated the increased $A\beta$ staining and astrocyte activation. We also found that $A\beta$ 42 injection decreased the MMN response and theta power/coherence of AERPs, suggesting an impairing effect on auditory discrimination and echoic memory processes. RA treatment reversed the $A\beta$ 42 related alterations in AERP parameters. In conclusion, our study demonstrates that RA prevented $A\beta$ -induced antioxidant-oxidant imbalance and cholinergic damage, which may contribute to the improvement of neural network dynamics of auditory processes in this rat model.

Key words: Amyloid β , Rosmarinic acid, Lipid peroxidation, Antioxidant system, Cholinergic system, Auditory event related potential.

Introduction

Alzheimer's disease (AD) is a neurodegenerative disease which is the most commonly recognized cause of dementia in the aging population (Brookmeyer et al., 2007). All forms of AD are characterized by extraneuronal deposits of amyloid β ($A\beta$) peptide and the intraneuronal accumulation of hyperphosphorylated tau (Blennow, 2006 #2310). Although the cause of AD is still unknown, previous studies highlighted the role of $A\beta$ peptides in the pathogenesis of the disease. In the amyloid cascade hypothesis, it is assumed that increased $A\beta$ accumulation has a pivotal role in the pathological cascades causing to increased oxidative stress, activation of astrocytes, neuronal dysfunction and loss, ultimately leading to cognitive dysfunction (Butterfield, 2002, Palop and Mucke, 2010). It is known that cholinergic neurons are more vulnerable to $A\beta$ toxicity. Although the role of cholinergic dysfunction in the etiology of AD is controversial, observed cholinergic abnormalities in AD patients and well-established role of cholinergic system in cognition support the idea that the reduced cholinergic neurotransmission is implicated in AD pathogenesis (Perry et al., 1981, Whitehouse et al., 1982). In a previous report, it was proposed that the reduction of cholinergic activity may weaken the compensatory capacity of the brain for secondary insults (Craig et al., 2011). Thus, the mechanisms by which $A\beta_{42}$ induces cholinergic dysfunction may involve the production of toxic mediators such as reactive oxygen intermediates.

Accumulating evidence indicates that increased oxidative stress plays an important role in the etiology and progression of AD. It is known that $A\beta$ peptide, as a mediator of oxidative stress, causes lipid peroxidation, protein oxidation, and thereby contribute to the pathological condition (Lauderback et al., 2001, Butterfield, 2002). Oxidative stress is caused by the imbalance between the rate of oxidants production and the level of antioxidants. Because of low activity of

antioxidant defense system and high content of polyunsaturated fatty acids, brain is susceptible to oxidative stress more than the other organs. Studies showing decreased glutathione content and altered enzyme activities in several brain regions of AD patients indicate that antioxidant defense system is affected in the AD (Gsell et al., 1995, Kim et al., 2003). In this context, the use of natural compounds containing a high concentration of antioxidants in the prevention and treatment of AD is a promising strategy. Naturally occurring antioxidants such as polyphenolic compounds have received great attention because they are perceived as safe and multifunctional compounds to treat the neurodegenerative diseases. Previous studies revealed that rosmarinic acid (RA) is one of the most potent antioxidant among the hydroxycinnamic group of polyphenols (Soobrattee et al., 2005) which was associated with improved antioxidant potency, including enhanced glutathione content and activity of antioxidant enzymes in vitro (Fallarini et al., 2009, Chkhikvishvili et al., 2013). In addition, RA also possesses multiple biological activities such as anti-inflammatory and anti-amyloidogenic effects (Makina et al., 2002, Ono et al., 2012). A few studies (El Omri et al., 2010, Mushtaq et al., 2014) showed the modulatory effect of RA containing extracts on cholinergic system but the effect of RA on A β 42 induced cholinergic deficit is largely unknown.

Several auditory tests such as the dichotic digits and phoneme discrimination were used to examine the auditory functions in patients and these studies concluded that central auditory processing impairs in individuals with AD (Iliadou and Kaprinis, 2003, Gates et al., 2011). Furthermore, earlier studies suggested that there is an association between cognitive decline and central auditory dysfunction (Gates et al., 2011). As it is an early symptom of the disease, it is important to examine how A β contributes to the auditory impairment. To do so, we examined the altered brain activity in the auditory event related potentials (AERPs) and relevant biochemical changes. Electrophysiological correlate of auditory sensory memory is the AERP component

1
2
3
4 named mismatch negativity (MMN). MMN is related to involuntary attention and reflects the
5
6 brain's capacity to discriminate sounds regardless of the individual's attentional and behavioral
7
8 capacity. Initially described by Näätänen et al. (1978) (Naatanen et al., 1978), MMN is a
9
10 cortically evoked potential that is detectable when a change occurs in the middle of a sequence of
11
12 repeated acoustic stimuli. On the other hand, MMN (MMN like AERP) have also been recorded
13
14 in various nonhuman animal species including primates and rats (Javitt et al., 1992, Eriksson and
15
16 Villa, 2005). In awake and anesthetized rats, the MMN has been found to occur in the latency
17
18 range of 30–250 ms (Ruusuvirta et al., 1998, Nakamura et al., 2011). So, MMN may be a good
19
20 indicator of auditory dysfunction in A β induced rat model of AD. To date, effects of RA on
21
22 AERPs in the A β induced AD animal model have not yet been investigated. Therefore, the goal
23
24 of the present study was to investigate possible protective effect of RA on neuronal toxicity of A β
25
26 in the auditory system which was evaluated through AERPs, neurochemical and
27
28 histopathological analyses. In order to evaluate the relationship between oxidative cell injury,
29
30 cholinergic markers and differences in AERP parameters, thiobarbituric acid reactive substances
31
32 (TBARS), 4-hydroxy-2-nonenal (4-HNE) levels, acetylcholine (ACh) content and acetylcholine
33
34 esterase (AChE) activity of the brain tissue were determined in the present research. Additionally,
35
36 to examine the antioxidant defense system, glutathione (GSH) content, superoxide dismutase
37
38 (SOD), glutathione peroxidase (GSH-Px) and catalase (CAT) activities were determined.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Materials and Methods

Animals and treatment

All animal experiments were approved by the Institutional Animal Care and Use Committee at Akdeniz University Medical School. Male albino Wistar rats aged 3 months, weighing 250 to 300 g were housed in stainless steel cages in groups of 4 rats per cage and given food and water *ad libitum*. Animals were maintained at 12 h light-dark cycles and a constant temperature of $23 \pm 1^\circ\text{C}$ at all times. Animals were divided into four groups (n=10 each group): (1) sham operated plus physiological saline treatment (S); (2) sham operated plus RA treatment (SR); (3) A β 42 (2.2 nmol/10 μl) i.c.v. (intracerebroventricularly) injection plus physiological saline treatment (A β); (4) A β 42 (2.2 nmol/10 μl) i.c.v. injection plus RA treatment (50 mg/kg, i.p.) (A β R). Drug treatment began one day after the surgical procedure. Treatment occurred once a day for 15 days. RA was purchased from Carbosynth (Carbosynth, San Diego, CA, USA). The purity of RA was >98%. RA has a molecular formula of $\text{C}_{18}\text{H}_{16}\text{O}_8$, and molecular weight of 360.31 g/mol. 50 mg of RA were dissolved in 1 ml 0.9% saline solution. The dosage was chosen according to the results of our earlier study (Gok et al., 2015). A β 42 (Sigma Chemicals, USA, product no: A9810) was diluted in sterile normal saline to a final concentration of 1 $\mu\text{g}/\mu\text{l}$. To obtain the aggregated form of A β 42, the peptide solution was placed in an incubator at 37°C for 72 h.

Animal preparation

The rat model of AD was established as described previously (Li et al., 2010). Rats were anesthetized with a combination of ketamine (80 mg/kg, i.p.) and xylazine (5 mg/kg, i.p.) and then placed in a standard stereotaxic apparatus. A middle sagittal incision was made in the scalp and was sterilized using standard procedures. Bilateral holes were drilled in the skull using a

1
2
3
4 dental drill over the lateral ventricles. Injection coordinates were chosen according to the atlas of
5
6 Paxinos and Watson (AP: -0.8mm, ML: $\pm$ 1.4mm, DV: -4.0 mm). Rats in A β and A β R groups
7
8 were injected with 2,2 nmol/10 μ l A β 42 at a rate of 0.5 μ l/min. The syringe was removed 5 min
9
10 after the injection. The S and SR groups received sterile normal saline. After surgery, the scalp
11
12 was sutured, and sulfamethoxazole was sprinkled on the wound to prevent infection. In addition,
13
14 penicillin (40,000 U) was injected intramuscularly into the gluteus, once a day for 3 days.
15
16
17
18
19

20 Biochemical Measurements

21
22 After the experimental period, animals were sacrificed by an overdose injection of anesthetic
23
24 agent the next day at the same time interval (9:00 am and 2:00 pm). Brain tissues were collected
25
26 and immediately stored in ice-cold buffer. The isolated brain tissues were homogenized
27
28 separately for TBARS/CAT (50mM potassium phosphate, pH 7.0, containing 1mM EDTA),
29
30 GSH-Px (50mM Tris-HCL, containing 5mM EDTA, and 1mM DTT, pH 7.5), SOD (2-5 ml
31
32 HEPES buffer), 4-HNE/GSH (5-10 ml PBS, pH 7.4) and ACh/AChE (20 mM sodium phosphate
33
34 buffer, pH 7.4).
35
36
37
38

39 Thiobarbituric acid reactive substances assay

40
41
42 A part of sonicated samples were centrifuged at 14,000 g for 10 min at 4 °C in an eppendorf
43
44 microcentrifuge (Biofuge 15R, Heraeus Sepatech, Osterode, Germany). The supernatant of
45
46 centrifuged samples was used for the assay of TBARS measurements. Levels of TBARS were
47
48 measured by a fluorimetric method described by Wasowicz et al. (1993) (Wasowicz et al., 1993),
49
50 using 1,1,3,3-tetraethoxypropane as a standard. The results are reported as μ mol/g protein.
51
52
53
54
55

56 4-Hydroxy-2-nonenal assay

The quantity of HNE adduct in protein samples was detected by 4-HNE Adduct ELISA kit (Cat# STA-838; OxiSelect; Cell Biolabs Inc., San Diego, CA) according to the manufacturer's instruction. In this kit, Bovine serum albumin (BSA) standards or protein samples (10 µg/ml) are adsorbed onto a 96-well plate for 2 hrs at 37°C. The HNE-protein adducts present in the sample and standard are probed with an anti-HNE antibody, followed by a HRP conjugated secondary antibody. The HNE-protein adducts content in an unknown sample is determined by comparing with a standard curve that is prepared from predetermined HNE-BSA standards. The quantity of HNE adduct was expressed in µg per mg protein.

Measurement of superoxide dismutase activity

The SOD activity was measured using assay kit (Cat #706002; Cayman Chemical, Ann Arbor, MI, USA) according to manufacturer's instruction. This kit utilizes a tetrazolium salt for the detection of superoxide radicals generated by xanthine oxidase and hypoxanthine. One unit of SOD was defined as the amount of enzyme needed to produce 50% dismutation of superoxide radical. SOD activity was expressed in unit per µg protein.

Measurement of catalase activity

The CAT activity was measured using assay kit (Cat #707002; Cayman Chemical, Ann Arbor, MI, USA) according to manufacturer's instruction. This kit utilizes the peroxidatic function of CAT for determination of enzyme activity. The method is based, briefly, on the reaction of enzyme with methanol in the presence of an optimal concentration of H₂O₂. The formaldehyde produced is measured colorimetrically with 4-amino-3-hydrazino-5-mercapto-1,2,4-triazole (Purpald) as the chromogen. One unit of CAT activity was defined as the amount of enzyme that

causes the formation of 1.0 nmol of formaldehyde per minute at 25°C. CAT activity was expressed in unit per µg protein.

Measurement of glutathione peroxidase activity

The GSH-Px activity was measured using assay kit (Cat #703102; Cayman Chemical, Ann Arbor, MI, USA) according to manufacturer's instruction. The measurement of GSH-Px activity is based on the principle of a coupled reaction with glutathione reductase (GR). The oxidized glutathione (GSSG) formed after reduction of hydroperoxide by GSH-Px is recycled to its reduced state by GR in the presence of nicotinamide-adenine dinucleotide phosphate (NADPH). The oxidation of NADPH is accompanied by a decrease in absorbance at 340 nm. One unit of GSH-Px was defined as the amount of enzyme that catalyzes the oxidation of 1 nmol of NADPH per minute at 25°C. GSH-Px activity was expressed in unit per mg protein.

Measurement of total glutathione

The GSH levels were measured by a commercially available GSH assay kit (Cat #703002; Cayman Chemical, Ann Arbor, MI, USA). Supernatants were deproteinated in 10% metaphosphoric acid (Sigma Aldrich, Steinheim, Switzerland). The GSSG was reduced to GSH by GSH reductase in the assay cocktail of the kit containing 5,5'-dithiobis-2-nitrobenzoic acid (DTNB), glucose-6-phosphate dehydrogenase, GSH reductase, Nicotinamide adenine dinucleotidephosphate (NADP+) and glucose-6-phosphate. The sulfhydryl group of GSH reacts with DTNB to give a yellow colored 5-thio-2-nitrobenzoic acid (TNB) which is measured at an absorbance of 405 nm. The values of total GSH for each sample were calculated from their respective slopes using a GSSG or GSH standard curve. Total GSH levels were expressed in mmol per mg protein.

Measurement of acetylcholine level

The ACh level was measured using an Amplex® Red Acetylcholine/Acetylcholinesterase Assay Kit (A-12217; Invitrogen, USA). According to the manufacturer's instructions, reactions were initiated by adding 100 µl of the working solution, containing 400 µM Amplex Red reagent, 2 U/ml horseradish peroxidase (HRP), 0.2 U/ml choline oxidase, and 1 U/ml acetylcholinesterase, to each microplate well containing 100 µl of the standard or test sample. Each reaction was incubated for 1 h at room temperature with plate agitation and protection from light. Absorbance was then measured using a microplate reader (Molecular Devices, USA) at a wavelength of 563 nm. Acetylcholine levels were calculated from a standard curve and expressed as mmol/g protein.

Measurement of acetylcholinesterase activity

The AChE activity was also measured using an Amplex® Red Acetylcholine/Acetylcholinesterase Assay Kit (A-12217; Invitrogen). A working solution, containing 400 µM Amplex Red reagent, 2 U/ml HRP, 0.2 U/ml choline oxidase, and 100 µM acetylcholine, was used for AChE activity measurement. Absorbance was measured using a microplate reader (Molecular Devices, USA) at a wavelength of 590 nm.

Determination of protein

Protein concentrations in brain tissues were spectrophotometrically measured (Shimadzu RF-5500, Kyoto, Japan) by a protein assay reagent kit (Pierce, Rockford, IL) via a modified Bradford method. Bovine serum albumin was used as a standard.

Pathologic examination and immunohistochemistry

Brain tissue was fixed with formaldehyde for pathologic examination. Formalin fixed brain tissues were sliced in coronal sections and whole brain were processed. Paraffin embedded tissues were cut in 4 μ m thick sections and were stained with Hemotoxylin&Eosin. They were examined blindly on light microscopy by one pathologist. The sections containing auditory cortex and hippocampus were selected for immunohistochemical analyzes. All sections were examined on a Zeiss-Axioplan, microscope (Zeiss, Oberkochen, Germany).

Immunohistochemical staining was performed by using Ventana Benchmark LT (Ventana Medical Systems, Tucson, AZ, USA) with its standard protocol. Briefly, selected paraffin embedded blocks was cut into 4- μ m-thick sections. Sections were incubated at 60°C for 5 min and then incubated with polyclonal rabbit anti-rat A β antibody (1:1000) (Cell Signaling, Beverly, MA, USA) and GFAP antibody (1:250) (Abcam, ab7260, USA) using a closed-system automated immunohistochemical staining device (Ventana, Roche, United States). A β 42 levels and GFAP expression were quantified using Image J (1.48v) software (NIH, USA), which confers semi-quantitatively analysis of immunohistochemical staining.

MMN recordings and analysis

At the end of the experiment, rats were anesthetized with intraperitoneal injections of urethane (1.2 g/kg, Sigma-Aldrich, St Louis, Missouri, USA) and prepared for MMN recordings. Briefly the head of the anesthetized animal was attached to the standard stereotaxic frame and six screws were placed in the skull. Recording electrodes were placed bilaterally on frontal and auditory cortex and reference and ground electrodes were placed on cerebellar skull. The tip of a stainless steel wire was positioned to the surface of the dura on the basis of online-recorded potentials to click stimuli. After the surgery, the ear bars were removed. The anesthetized animal was then

1
2
3
4 moved into a sound-attenuated recording room. Mean background noise level of the recording
5
6 room measured 46 dB with a sound level meter (Testo 816 Sound Level Meter, Germany).
7

8
9 AERPs were recorded using the oddball condition, experimental set-up adapted and modified
10
11 from Astikainen et al. (Astikainen et al., 2011). In the oddball condition for auditory stimuli,
12
13 frequencies of standard and deviant tones were 2000 and 2500 Hz, respectively. Deviant tones
14
15 were pseudorandomized to occur at a 10% probability (900 standard tones, 100 deviant tones) in
16
17 a sequence of standard tones. In the oddball, two separate stimulus blocks were presented with
18
19 interstimulus intervals of 375 and 600 ms. The tones were ordered pseudorandomly in their series
20
21 with the restriction that there were no less than two standards between consecutive deviants. The
22
23 duration of the 85-dB tones was 50 ms and the tones were presented through a loudspeaker at a
24
25 distance of 15 cm from the ears of the animal.
26
27
28
29

30
31 Electroencephalogram signal was amplified (Brainamp EEG/EP Amplifier, Brain Products,
32
33 Munich, Germany), band-pass filtered (0.1–300 Hz), and digitized at a 1000-Hz sampling rate
34
35 (Brainvision Recorder, Brain Products, Munich, Germany). Data recorded during oddball
36
37 condition were filtered (0.1–150 Hz) and baseline corrected (the average amplitude of a 50-ms
38
39 period preceding stimulus onset) (Brainvision Analyzer, Brain Products, Munich, Germany). For
40
41 both ISI value, the following averaged curves were computed for each animal and then for all
42
43 groups of animals: Standard before deviant (StbD) (AERPs to standard tones preceding deviant
44
45 tones), Deviant (Dev) (AERPs to all deviant tones during the oddball paradigm). The peak-to
46
47
48
49 peak amplitudes and latencies of the P1, N1, P2 and N2 components of the AERPs were
50
51 determined for each rat from the averaged StbD and Dev curves within the time period of 0–350
52
53 from stimulus onset.
54
55
56
57
58
59
60
61
62
63
64
65

MMN response was obtained by subtracting the averaged curves corresponding to the StbD stimulus from the averaged curves obtained in response to the Dev stimulus. The MMN was identified as the wave of negative polarity and with approximate latency of 50-200 ms post-stimulus. Because the MMN was defined as the part of the AERP wave where there is a significant difference between deviant and standard responses, AERP curves in this time window were submitted to paired sample t-test and repeated measures of ANOVA (for stimulus effect) to verify the MMN response. Amplitude measurements were analyzed and calculated by placing one of the reference cursors on the negative polarity point and the other cursor on the positive point previous to MMN between 50–200 ms.

Power spectrum analysis

The epochs (0 -375 ms, 0-600 ms) of each rat were averaged for each electrode location and then the digital FFT-based power spectrum analysis was performed using a Hanning window with 10% taper length with brainvision analyzer. The standard frequency band of interest was theta (4–8 Hz). At this point, the theta frequency range was chosen for investigating the Aβ induced effects on AERPs, since the role of theta oscillations in discrimination process and MMN generation was identified in the previous studies (Ko et al., 2012, Kaser et al., 2013). The maximum individual theta frequency value for each rat was included, for the purpose of statistical analysis, as the maximum individual theta frequency value of that rat.

Coherence

Coherence was calculated with BrainVision Analyzer using the following equation:

$$\text{Coh}(c_1, c_2)(f) = |CS(c_1, c_2)(f)|^2 / (|CS(c_1, c_2)(f)| |CS(c_1, c_2)(f)|)$$

where $CS(c_1, c_2)(f) = \sum c_{1, i}(f) c_{2, i}(f)$. For the theta frequency band (4–8 Hz), coherence values were computed from the cross spectrum for the target stimuli for intrahemispheric and interhemispheric electrode pairs.

Statistical analysis

The statistical analysis of the obtained data was performed by SPSS 18.0 (SPSS, Chicago, IL, USA) software for Windows. Statistical comparisons between groups for all biochemical parameters were performed by using one way ANOVA and post-hoc Bonferroni test. Statistical comparisons between groups for GFAP and A β staining were performed by using Kruskal-Wallis one-way analysis of variance and Mann-Whitney U test.

The latencies and peak to peak amplitudes of P1, N1, P2 and N2 components of the AERPs and theta power were analyzed by means of a repeated measure ANOVA including the between subject factor groups (S, R, A β , A β R) and the within subject factor locations (F_{left} , F_{right} , AC_{left} , AC_{right}), stimulus (Dev, StbD) (Bonferroni post hoc test). Greenhouse–Geisser corrected p-values are reported. The comparisons of P2N2 responses between the two stimulus levels for each group were made using the paired sample t-test. MMN amplitudes were examined via repeated measure ANOVA included between subject factor groups (S, R, A β , A β R), and within-subject factor locations (F_{left} , F_{right} , AC_{left} , AC_{right}). Post hoc comparisons were analyzed with Bonferroni test. The coherence values were analyzed by a repeated measures ANOVAs with one between subject factor(S, R, A β , A β R), and two within-subject factors (ISI: 375, 600; electrode pairs)(Bonferroni post hoc test). Separate repeated measures ANOVAs were conducted for the intrahemispheric and interhemispheric electrode pairs for theta frequency band.

Results

Thiobarbituric acid reactive substances levels

Lipid peroxidation was measured as the amount of TBARS. Mean TBARS values of the brain tissues of sham and experimental groups are given in Fig. 1A. There was a statistically significant difference between groups [$F_{3,36} = 12.83$, $p < 0.001$]. Brain TBARS levels were significantly increased in the A β (0.33 ± 0.02 $\mu\text{mol/g}$ protein) group versus the S (0.26 ± 0.01 $\mu\text{mol/g}$ protein) and SR (0.19 ± 0.02 $\mu\text{mol/g}$ protein) groups ($p < 0.01$ for all comparisons). RA treated-A β R (0.21 ± 0.02 $\mu\text{mol/g}$ protein) group had lower TBARS levels versus the A β group ($p < 0.001$). RA treatment alone had no impact on TBARS level in the SR group when compared to S group.

4-Hydroxy-2-nonenal levels

Mean values of brain 4-HNE levels are given in Fig. 1B. There was a statistically significant difference in 4-HNE levels between groups [$F_{3,36} = 17.25$, $p < 0.001$]. Brain 4-HNE levels were significantly increased in the A β (1.85 ± 0.05 $\mu\text{g/mg}$ protein) group with respect to S (1.42 ± 0.04 $\mu\text{g/mg}$ protein) and SR (1.35 ± 0.06 $\mu\text{g/mg}$ protein) groups, and significantly decreased in the A β R (1.36 ± 0.06 $\mu\text{g/mg}$ protein) group versus the A β group ($p < 0.001$ for all comparisons).

Superoxide dismutase activity

SOD activities of the brain tissues of all experimental groups are shown in Fig. 2A. There was a statistically significant difference between groups [$F_{3,36} = 23.19$, $p < 0.001$]. SOD activity was significantly attenuated in the A β (0.12 ± 0.02 U/ μg protein) group in comparison with S (0.19 ± 0.02 U/ μg protein) and SR (0.25 ± 0.01 U/ μg protein) groups ($p < 0.001$ for all comparisons). SOD activity was significantly increased in the A β R (0.29 ± 0.02 U/ μg protein) group with

respect to A β group ($p < 0.001$). Although a slight increase was seen in the SOD activity of SR group, this increment did not reached the significant level.

Catalase activity

CAT activities in the brain tissues of all experimental groups are presented in Fig. 2B. There was a statistically significant difference between groups [$F_{3,36} = 46.27$, $p < 0.001$]. CAT activity was significantly decreased in the A β (0.13 ± 0.02 U/ μ g protein) group as compared to S (0.32 ± 0.01 U/ μ g protein) and SR (0.39 ± 0.03 U/ μ g protein) groups ($p < 0.001$ for all comparisons). The activity of CAT was significantly increased in the RA treated A β R (0.45 ± 0.01 U/ μ g protein) group versus the A β and also S group ($p < 0.001$). RA treatment alone was slightly increased the CAT activity in the SR group but this increment did not reached the significant level.

Glutathione peroxidase activity

GSH-Px activities of the brain tissues of sham and experimental groups are shown in Fig. 2C. There was a statistically significant difference between groups [$F_{3,36} = 33.55$, $p < 0.001$]. GSH-Px activity was significantly decreased in the A β (0.66 ± 0.04 U/mg protein) group versus S (1.00 ± 0.08 U/mg protein) and SR (1.12 ± 0.07 U/mg protein) groups ($p < 0.001$ for all comparisons). The activity of GSH-Px was significantly increased in A β R (1.21 ± 0.05 U/mg protein) group versus the A β ($p < 0.001$) and also S ($p < 0.01$) and SR groups ($p < 0.05$). RA treatment alone slightly increased the GSH-Px activity in the SR group but this increment did not reached the significance level.

Glutathione Levels

Mean values of brain GSH level are given in Fig. 2D. There was a statistically significant difference in GSH levels between groups [$F_{3,36} = 106.61$, $p < 0.001$]. Brain GSH levels were significantly decreased in the A β (1.03 ± 0.05 mmol/mg protein) group with respect to S (2.61 ± 0.09 mmol/mg protein) and SR (2.85 ± 0.12 mmol/mg protein) groups. Although GSH level was significantly increased in the A β R (1.49 ± 0.03 mmol/mg protein) in comparison to the A β group ($p < 0.01$), it did not reach to sham level.

Acetylcholine levels

Mean values of brain ACh levels are given in Fig. 3A. There was a statistically significant difference in ACh levels between groups [$F_{3,36} = 65.51$, $p < 0.001$]. Brain ACh levels were significantly decreased in the A β (4.99 ± 0.38 mmol/g protein) group versus S (8.88 ± 0.42 mmol/g protein) and SR (11.60 ± 0.43 mmol/g protein) groups. The decrement in the ACh level was reversed by the RA administration and also increased versus the S group in the A β R (12.79 ± 0.50 mmol/g protein) group ($p < 0.001$ for all comparisons). RA treatment alone was slightly increased the ACh level in the SR group but this increment did not reached the significance level.

Acetylcholine esterase activity

AChE activities in the brain tissues of all groups are shown in Fig. 3B. There was a statistically significant difference between groups [$F_{3,36} = 23.29$, $p < 0.001$]. AChE activity was significantly attenuated in the A β (1.70 ± 0.12 U/mg protein) group with respect to S (3.02 ± 0.22 U/mg protein) and SR (3.90 ± 0.19 U/mg protein) groups ($p < 0.05$ for all comparisons). The AChE activity was significantly increased in A β R (4.10 ± 0.40 U/mg protein) group versus the A β and S groups ($p < 0.001$). RA treatment alone was slightly increased the AChE activity in the SR group but this increment did not reached the significance level.

Amyloid β and GFAP immunostaining

Immunohistochemical analysis of A β deposits and GFAP are shown in Fig. 4. There was a very little intraneuronal A β immunolabeling localized in hippocampal areas and auditory cortex of S and SR groups (Fig. 4A). On the other hand, intense A β immunoreactivity was clearly observed in the cytoplasm of hippocampal and auditory cortical areas in the A β group. A β immunostaining in the A β R group was not as intense as in the A β group. Quantitative analysis of A β stained sections revealed that there was a significant difference among groups (HC: $H(3) = 13.78$, $p < 0.01$; AC: $H(3) = 11.27$, $p < 0.05$) (Fig. 4B). Both in hippocampus and auditory cortex, higher A β immunoreactivity and percentage of stained area were detected in the A β group versus the S and SR groups ($p < 0.05$ for all comparisons). RA treatment significantly decreased A β staining in the A β R group versus the A β group (Fig. 4B) ($p < 0.05$ for all comparisons).

Normal astrocyte structure was observed in the hippocampal and auditory cortical areas of the S and SR groups (Fig. 4C). Intense GFAP immunostaining were detected in the hippocampus and auditory cortex areas of A β group. It was due to the increment in the number of astrocytes that have long, thick branching and distended cell body as an indicator of astrogliosis. RA significantly inhibited the A β 42 induced astrocytic reaction in hippocampus and auditory cortex (Fig. 4C). Quantitative analysis of GFAP stained sections revealed that there was a significant difference among groups (HC: $H(3) = 12.79$, $p < 0.01$; AC: $H(3) = 9.55$, $p < 0.05$) (Fig. 4D). Higher GFAP immunoreactivity and % stained area in the hippocampus and auditory cortex of A β group were decreased significantly attenuated in the A β R group (Fig. 4D) ($p < 0.05$ for all comparisons).

Auditory event related potentials and MMN response

Fig. 5 illustrates the P1, N1, P2 and N2 components of AERPs to StbD and Dev tones in the two oddball conditions for all experimental groups. Difference waveforms (DW) obtained by subtracting standard responses from deviant ones are also shown in the same figure (Fig. 5). Measurements were made on two positive and two negative potentials which were seen in all of the groups. In the present study, there was no main group effect on latencies of AERP components for both ISI values.

Mean $\pm$ SEM of peak-to-peak amplitudes of AERP components (P1N1, N1P2, P2N2) in response to StbD and Dev tones for 375 ms ISI are shown in Table 1. The analysis of amplitudes demonstrated that there was no main group effect for 375 ms ISI value for all AERP components. Mean $\pm$ SEM of peak-to-peak amplitudes of AERP components (P1N1, N1P2, P2N2) in response to StbD and Dev tones for 600 ms ISI are shown in Table 2. When we examined the amplitudes for 600 ms ISI value, repeated ANOVA indicated a significant group effect [$F_{3,36} = 1714.09$, $p < 0.001$]. Also, there was significant stimulus effect for N1P2 [Stim: $F_{1,36} = 683.57$, $p < 0.001$] and P2N2 amplitudes [Stim: $F_{1,36} = 763.92$, $p < 0.001$]. Post-hoc comparisons showed that N1P2 response to Dev stimulus was significantly smaller than N1P2 response to StbD stimulus in S and SR groups over the right frontal and auditory regions ($p < 0.001$ for all comparisons). For the A β group, we didn't observe the decrement in N1P2 amplitude to Dev stimulus and any amplitude difference between N1P2 responses to Dev and StbD stimulus ($p > 0.05$). RA treatment in the A β R group was reconstituted the decrement pattern and amplitude difference between N1P2 responses to Dev and StbD stimulus in right frontal and auditory regions ($p < 0.001$ for all comparisons).

In a reverse manner, P2N2 response to Dev stimulus was significantly larger versus P2N2 response to StbD stimulus in S and SR groups over the right frontal and auditory regions ($p <$

0.001 for all comparisons). This amplitude increment to Dev response was not observed in the A β group ($p > 0.05$). RA treatment reconstituted the increment pattern of P2N2 response in the A β R rats. In parallel, between group comparisons indicated that A β group had higher N1P2 amplitude than S and SR groups for Dev stimulus over right frontal ($p < 0.001$) and auditory regions ($p < 0.05$ for all comparisons). N1P2 amplitude significantly decreased and returned to sham level in the A β R group versus the A β group in the same electrode regions ($p < 0.01$ for all comparisons). In a similar manner, for Dev stimulus, P2N2 amplitude was decreased in the A β group versus the S and SR groups and significantly increased in the A β R group with respect to the A β group over the same regions ($p < 0.01$ for all comparisons).

There was no main group effect on MMN responses for 375 ms ISI value. When we examined the MMN amplitudes for 600 ms ISI value, repeated ANOVA indicated a significant group effect [$F_{3,36} = 22.17$, $p < 0.001$]. Post-hoc comparisons showed that MMN response was significantly decreased in the A β group in comparison to S and SR groups over right and auditory regions ($p < 0.01$ for all comparisons). MMN amplitude was significantly reversed to sham level by rosmarinic acid administration in the A β R group.

Mean $\pm$ SEM of theta power values of AERPs in response to StbD and Dev tones for 375 and 600 ms ISI values are shown in Table 3. In the present study, we did not observe any difference between groups in terms of theta power values for 375 ms ISI value. However, there was significant stimulus effect [$F_{1,36} = 115.68$, $p < 0.001$] for theta power. Post-hoc analysis showed that theta power was significantly increased in response to Dev stimulus versus the StbD stimulus over the left frontal and auditory regions in all groups. For 600 ms ISI value, we observed a significant main effect of group on theta power of AERPs [$F_{3,36} = 10.98$; $p < 0.001$]. Moreover, there was also significant stimulus effect [$F_{1,36} = 145.96$, $p < 0.001$] independent of groups. Post-

1
2
3
4 hoc analysis showed that there was no significant difference between theta power for Dev and
5
6 StbD stimulus in A β group. For Dev stimulus, theta power was significantly decreased in the A β
7
8 group in comparison to S and SR groups over right and auditory regions ($p < 0.01$ for all
9
10 comparisons). Theta power value was significantly reversed to sham level by RA administration
11
12 in the A β R group.
13
14

15
16
17 Mean $\pm$ SEM of theta coherence values of AERPs in response to StbD and Dev tones for 375 and
18
19 600 ms ISI values are shown in Table 4. In the analysis of interhemispheric coherence
20
21 differences, the ANOVA on theta coherence revealed a significant group effect [$F_{3,36} = 25.05$, $p <$
22
23 0.01]. Moreover, there were significant stimulus [$F_{1,36} = 10.73$, $p < 0.01$] and [$F_{1,36} = 408.26$, $p <$
24
25 0.001] electrode pairs effects. However, there was no significant ISI effect [$F_{1,36} = 1.04$, $p > 0.05$].
26
27 These results indicate an increase in theta coherence over auditory electrode pairs for Dev
28
29 stimulus in both ISI values. Post-hoc comparisons showed that theta coherence was significantly
30
31 lower for A β group than S and SR groups at the auditory electrode pair for Dev stimulus in both
32
33 ISI values ($p < 0.001$ for all comparisons). RA administration was significantly increased the
34
35 decreased theta coherence values over auditory electrode pairs in the A β R group compared to A β
36
37 group. The analysis of intrahemispheric coherence revealed no significant main and interaction
38
39 effect for any of these parameters.
40
41
42
43
44
45
46

47 **Discussion**

48
49 In the present study, we used a rat model of AD based on the i.c.v. application of A β 42 to
50
51 induce the changes similar to AD pathology. Similar to transgenic models, exogenous A β
52
53 administration does not reproduce the full complexity of the human AD pathology. However,
54
55 there is an impressive amount of evidence showing that exogenous administration of various A β
56
57 peptides have been reported to induce considerable grade of neurodegeneration and glial
58
59
60
61
62
63
64
65

1
2
3
4 activation, as well as a reduction in levels of ACh, proximal to A β deposits (LaFerla et al., 1995,
5
6 Pepeu et al., 1996).

7
8
9 Oxidative stress which resulted from an overproduction of reactive oxygen species (ROS)
10
11 or from a reduction in antioxidant defenses has been suggested to be a primer initiating factor or
12
13 contributor to the neurodegeneration seen in AD (Filipcik et al., 2006, Ansari and Scheff, 2010).
14
15 In this respect, TBARS and 4-HNE levels were considered in the current study since they have
16
17 been widely used as markers of lipid peroxidation caused by oxidant stress. Our data have shown
18
19 that A β 42 injection significantly increased TBARS and 4-HNE levels in rats compared with
20
21 sham group. Our finding is in agreement with earlier studies indicated that A β peptides promotes
22
23 oxidative stress and directly responsible for free-radical damage to neuronal membrane systems
24
25 that lead to subsequent increase in lipid peroxidation (Butterfield, 2002, Palop and Mucke, 2010).
26
27 Hence, our findings suggest that oxidative stress plays a central role in the pathogenesis of AD,
28
29 because the formation of toxic lipid peroxidation causes peroxidative damage of membrane
30
31 structure and changes in associated enzymes, receptors and physiological functions, that may
32
33 ultimately result in disturbances in neuronal functions. On the other hand, we determined SOD,
34
35 CAT, GSH-Px activities and GSH levels to examine the antioxidant defense system. We found a
36
37 significant reduction in SOD/CAT and GSH/GSH-Px system that is in accordance with the
38
39 findings of some animal and human studies (Kaminsky and Kosenko, 2008, Padurariu et al.,
40
41 2010, Puertas et al., 2012). However, other studies in the literature reported contradictory
42
43 findings such as no change in GSH-Px (Marcus et al., 1998, Sultana et al., 2008), a significant
44
45 increase (Lovell et al., 1995) or no change (Gsell et al., 1995) in SOD or increased CAT activity
46
47 (Lovell et al., 1995) in AD. Nevertheless, collectively these findings suggest that A β 42 peptide
48
49 induce a general weakening in the antioxidant defense system which fails either due to
50
51 overproduction of free radicals or decrement in activities of scavenging enzymes. Regarding the
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 observed alterations in brain of AD rats, previous studies as well as the present findings support
5
6 the view that GSH level is a consistent marker for antioxidant status in A β treated animal models.
7
8 Because GSH is major antioxidant of the brain, its reduction leads to a situation where the rate of
9
10 ROS production exceeds the antioxidant ability and thereby generating a situation that favors
11
12 oxidative stress.
13
14

15
16 Extensive literature from human and animal studies supports the notion that cholinergic
17
18 dysfunction in the central nervous system is another important factor that contributes to the
19
20 molecular changes associated with AD (Whitehouse et al., 1982, Bartus and Emerich, 1999, Auld
21
22 et al., 2002). Within this context, we examined the ACh level and AChE activity to determine the
23
24 effect of A β peptide on cholinergic system. Consistent with earlier studies indicating a
25
26 relationship between cholinergic dysfunction and degree of A β deposition (Tran et al., 2002,
27
28 Parihar and Hemnani, 2004, Jicha and Carr, 2010), brain ACh level and AChE activity showed a
29
30 marked decrease in the A β injected rats versus the other groups. Several mechanisms can explain
31
32 the A β induced cholinergic damage. First, A β peptide interacts with some membrane receptors
33
34 that facilitate its internalization and thereby mediate its toxic effects directly in cholinergic cells.
35
36 Secondly, A β peptides activate several kinases such as mitogen-activated protein kinase and
37
38 glycogen synthase kinase-3 β which are known to be involved in tau phosphorylation and
39
40 thereby lead to neuronal death via disruption of the cytoskeletal network. Thirdly, long-term
41
42 exposure to A β peptide induces an increase in choline transmission that in turn leads to choline
43
44 depletion. As a consequence, usage of membrane phosphatidylcholine to synthesize ACh causes
45
46 disruption of membrane turnover and damage. Last, taking into account the peroxidative effect of
47
48 A β obtained in the present research as well as the previous studies showing the role of oxidative
49
50 stress in both kinase activation and cytotoxicity, it is conceivable to suggest that A β induced lipid
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 peroxidation may play an important role in the observed changes in cholinergic parameters. In
5
6 addition, considering the neuroprotective (neurogenesis, neurotrophic factors, changes in
7
8 dendritic branching role of ACh in the brain, reduction in ACh mediated compensatory
9
10 mechanisms may be an important factor in the enhancement of oxidative damage to the
11
12 membranes as we observed in the A β group. Consistent with this view, in a previous report it was
13
14 proposed that cholinergic depletion leads to a dampening in the ability of the brain to compensate
15
16 for secondary insults and augment the degenerative processes (Craig et al., 2011).
17
18
19
20
21

22 It is well known that reactive astrogliosis prominently takes place in AD pathology as an
23
24 inflammatory response and astrogliosis detected in the cortex and hippocampal areas of patients
25
26 with AD (Boekhoorn et al., 2006). In accordance with this previous report (Li et al., 2010), we
27
28 found a significant enhancement of GFAP immunoreactivity in hippocampus and auditory cortex
29
30 of A β 42 injected rats. This increase can be explained partly by hypertrophy and upregulation of
31
32 the GFAP expression in reactive astrocytes, which is considered to play a role in the events
33
34 involved in A β neurotoxicity.
35
36
37
38

39 There has been a growing interest in the potential use of natural polyphenols since recent
40
41 evidence has indicated that they have multiple biological activities which can be relevant to
42
43 reverse degenerative processes in many ways. Therefore, we investigated the protective effects of
44
45 RA, a naturally occurring hydroxylated polyphenolic compound, on A β induced neurotoxicity.
46
47 The current results clearly demonstrated that RA attenuated lipid peroxidation induced by A β .
48
49 Moreover, RA increased the SOD, CAT, GSH-Px activity and GSH level, suggesting that it was
50
51 also potentiated scavenge of ROS possibly by improving the activity of the antioxidant system.
52
53
54
55

56 Substantial evidence proposed that AD causes synaptic dysfunction early in the disease
57
58 process, disrupting communication within cholinergic neural circuits that are important for
59
60
61
62
63
64
65

memory and other cognitive functions. To increase levels of ACh by suppressing AChE activity is one of the main therapeutic approaches in AD. But, in the present study, we found that RA increased not only cortical ACh levels but also AChE activity in the A β R group. Therefore, we propose that RA has a potentiating effect on cholinergic system and consequently caused an increment in AChE activity. Our present data are compatible with the report of El Omri (El Omri et al., 2010) showing that RA might potentiate cholinergic system by increasing both ACh level and AChE activity. However, our findings contradict with some biochemical and animal studies which have reported anticholinesterase activity of RA and/or RA containing extracts (Mushtaq et al., 2014, Soodi et al., 2014, Vladimir-Knezevic et al., 2014). This contradiction could be attributed to the application and dose differences.

Our findings together with previous observations strongly suggest that RA may induce neuroprotection and may provide memory improvement against A β 42 peptide. Moreover, RA administration prevented the decrease of cholinergic markers in the brain of A β 42 injected rats. To the best of our knowledge, this is the first study that examined the effect of RA on cholinergic markers in A β induced neurotoxicity. Therefore, it is likely that the RA exerts protective effects against oxidative stress via preventing alterations in cholinergic activity. In addition, RA showed anti-amyloidogenic effect with decreased A β immunostaining and also decreased GFAP over expression in parallel with its antioxidant effects. Reduction in A β accumulation accompanied by increases in antioxidant defense and cholinergic markers may attenuate astrocyte activation. Consequently, the preventive effects of RA such as reducing lipid peroxidation and oxidative stress might be associated with the cholinergic property exhibited by this polyphenol.

In the current study, we recorded AERPs and analyzed the MMN response to determine the effects of RA to the central auditory dysfunction which seen in an early stage of AD.

Consistent with previous studies (Ruusuvirta et al., 1998, Eriksson and Villa, 2005, Astikainen et al., 2011), in comparison to standard tones, deviant tones elicited MMN response in shorter ISI over the left frontal and auditory regions in all experimental groups. Our data demonstrated that A β 42 peptide induced alterations did not interfere with the short-term echoic memory processes. In the right frontal area we did not observe any significant MMN response in sham group rats. In the light of these data, we suggest that the MMN generation might be left dominant over frontal areas. Our data is in parallel with a dynamic causal modeling study (Garrido et al., 2009) which showed that intrinsic connections within bilateral primary auditory cortices and extrinsically connections from right secondary auditory cortex to right frontal cortex were involved in MMN generation network. In contrast, human studies indicated right hemisphere dominance for tones (Levanen et al., 1996) and left hemisphere dominance for phonemes in deviant detection paradigms (Naatanen et al., 1997, Tervaniemi et al., 2000). On the other hand, our data clearly indicated that MMN responses in longer ISI were decreased in A β group in comparison with the sham group over the mentioned areas. It is plausible that increasing ISI value increases the echoic memory load in the system. Therefore, it could be expected that MMN response in AD patients were diminished in longer ISI assessed by study of Pekkonen (Pekkonen et al., 2001). Moreover, based on the elevated levels of TBARS and 4-HNE, we can conclude that lipid peroxidation might have a role in the altered auditory processing for long ISI value in this group. Additionally, decreased cholinergic markers in A β 42 administered rats might affect neuronal dynamics in the generation of MMN.

The power of the theta band oscillation showed a significant increase with the Dev stimulus. This significant increase is consistent with previous studies indicating that MMN is related with an increase in theta power in deviant tones (Ko et al., 2012, Kaser et al., 2013). Increased frontal

1
2
3
4 theta response has been associated with information processing and error monitoring (Basar-
5
6 Eroglu et al., 1992). In parallel with amplitude results, this increment in theta power was
7
8 diminished in A β group. As mentioned above, theta oscillations play an important role in the
9
10 generation of MMN component. Therefore, it could be concluded that A β peptide interfered with
11
12 the theta activity in the network. So, reduced MMN amplitude and theta spectral power of A β
13
14 injected rats in longer ISI suggest that even do their auditory discrimination ability is intact, their
15
16 echoic memory strength is impaired by A β exposure. Since AD patients have exhibited decreased
17
18 theta activity in cognition, findings of this study support the view that reduced theta power might
19
20 be the underlying oscillatory mechanism related to the decreased MMN amplitudes in patients.
21
22 Considering the heterogeneous nature of theta rhythms, several mechanisms should be considered
23
24 to explain these data. Previous reports indicate that cortical ACh modulate the general efficacy of
25
26 the cortical processing of sensory stimulus or associational information by enhancing the
27
28 influence of relevant stimulus for further processing (Sarter et al., 2005). For example, while
29
30 ACh reduces the intracortical synaptic potentials, facilitates the thalamocortical input to the
31
32 auditory cortex (Picciotto et al., 2012). In this way, ACh affects signal-to-noise ratio during
33
34 sensory processing and modulates synchronization of neuronal networks. Thus, the functional
35
36 role of ACh includes enhancement of both attention to sensory stimuli and encoding of memory
37
38 for specific stimuli. Furthermore, relationship between cholinergic transmission and cortical theta
39
40 oscillations was evidenced with the reduction in the event related theta power in the frontal cortex
41
42 of medial septal lesioned animals. Also, neocortical brain slices had been shown to display
43
44 oscillatory activity in the theta range when perfused with a cholinergic agonist (Lukatch and
45
46 MacIver, 1997). Within this context, we suggest that A β induced cholinergic hypofunction may
47
48 contribute to the observed decrement of theta power. Consequently, in agreement with earlier
49
50 studies, our data strongly suggests that cholinergic inputs to the auditory cortex play an important
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 role in stimulus specific adaptation, plasticity and sensory memory (Pekkonen et al., 2001, Leach
5
6 et al., 2013). Other possible mechanism might involve the impaired glutamatergic
7
8 neurotransmission that is known to play a significant role in pathophysiology of AD. Previous
9
10 research indicated that modulation of the glutamatergic system (via NMDA receptor modulation)
11
12 was associated with MMN generation in auditory cortex (Javitt et al., 1996). Also, NMDA
13
14 receptor blockade was shown to reduce theta frequency power (Lazarewicz et al., 2010) and
15
16 phase locking (van Wingerden et al., 2012) in experimental studies.
17
18
19
20
21

22 In the current study we found significant decrease in theta coherence for the Dev stimulus
23
24 that may reflect impaired cortical connectivity between cortical regions. Our results are in
25
26 agreement with previous studies showing decreased coherence activity in AD evidenced with
27
28 reduced resting states and evoked coherence in individuals with AD. Previously, it was proposed
29
30 that impaired neural synchrony results from neocortical disconnection syndrome induced by
31
32 degenerative processes (Delbeuck et al., 2003). Diffusion tensor imaging studies verified this
33
34 view with identified disintegration of white matter tracts (Medina et al., 2006, Naggara et al.,
35
36 2006). In addition, prominent accumulation of amyloid plaques was detected around cortical
37
38 tracts previously (Pearson et al., 1984). Based on the foregoing findings, we concluded that the
39
40 A β 42 induced degenerative changes in the white matter might contribute to decrement of theta
41
42 coherence. On the other hand, in line with our data, reduced cholinergic transmission with
43
44 muscarinic antagonist, scopolamine, altered the interhemispheric functional connectivity during
45
46 rest and photic stimulus (Ebert and Kirch, 1998). Based on the determined role of ACh in encoding
47
48 novel information in hippocampus and also in sensory system, we suggest that reductions of ACh might
49
50 play a role in the observed attenuation of theta synchronization during Dev stimulus. The
51
52 evidence that cholinergic projections to the cerebral cortex are necessary for the beta and gamma
53
54
55
56
57
58
59
60
61
62
63
64
65

band synchronization (Rodriguez et al., 2004) is compatible with this hypothesis. Here, we demonstrated that 50 mg/kg RA treatment significantly reversed the A β induced changes in MMN response and theta dynamics. Moreover, in two different analyses we found that both A β induced decrement in theta power and auditory theta coherence were prevented by RA administration.

In conclusion, our results are consistent with previous findings that A β 42 peptide induces lipid peroxidation, cholinergic dysfunction, and astroglial activation together with a general decrement in antioxidant capacity. Observed difference in AERPs and MMN only for longer ISI values indicates that A β 42 effects sensory memory while not disturbing auditory perception. Furthermore, oral RA administration which prevent A β 42 induced disruption of network dynamic underline MMN generation and thereby preserve echoic memory possible by increasing cholinergic tone and suppressing oxidative stress via attenuating lipid peroxidation and potentiating antioxidant defense. Thus, RA could be used as an efficient agent to prevent diverse pathological processes, which are also related with each other in different levels, with its multiple bioactivities.

Conflict of interest

There were no conflicts of interest reported by the authors of this paper.

Acknowledgement:

This study was supported by a grant from Akdeniz University Research Foundation, Turkey (Grant No: 2013.03.0122.013).

Legends of Figures

Fig. 1.

TBARS and 4-HNE levels of the brain tissues in sham and experimental groups. The results are presented as mean±SEM, n=10 for each group. (*significant vs. S group; ^ξsignificant vs. Aβ group)

Fig. 2.

SOD, CAT, GSH-Px activities and GSH levels of the brain tissues in sham and experimental groups. The results are presented as mean±SEM, n=10 for each group. (*significant vs. S group; ^ξsignificant vs. Aβ group)

Fig. 3.

ACh levels and AChE activities of the brain tissues in sham and experimental groups. The results are presented as mean±SEM, n=10 for each group. (*significant vs. S group; ^ξsignificant vs. Aβ group)

Fig. 4.

Immunohistochemical staining of Aβ peptide and GFAP protein in all experimental groups. Representative images of; Aβ peptide localization in the hippocampus and auditory cortex, GFAP localization in the hippocampus and auditory cortex. The scale bar is 20 μm. At the bottom panel: Quantitative analysis of; A: Aβ staining levels in the hippocampus, B: Aβ staining levels in the auditory cortex, C: GFAP staining levels in the hippocampus, D: GFAP staining levels in the

auditory cortex. Results are mean $\pm$ SEM, n=5 for each group. (*significant vs. S group; [‡]significant vs. A β group)

Fig. 5.

Representative AERP responses to Standard (StbD) and deviants (Dev) tones in the oddball condition and the difference waves (DW) in the left auditory location for all groups. Two positive (P1,P2) and two negative (N1,N2).

References

- Ansari MA, Scheff SW (2010) Oxidative stress in the progression of Alzheimer disease in the frontal cortex. *J Neuropathol Exp Neurol* 69:155-167.
- Astikainen P, Stefanics G, Nokia M, Lipponen A, Cong F, Penttonen M, Ruusuvirta T (2011) Memory-based mismatch response to frequency changes in rats. *PloS one* 6:e24208.
- Auld DS, Kornecook TJ, Bastianetto S, Quirion R (2002) Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. *Prog Neurobiol* 68:209-245.
- Bartus RT, Emerich DF (1999) Cholinergic markers in Alzheimer disease. *Jama* 282:2208-2209.
- Basar-Eroglu C, Basar E, Demiralp T, Schurmann M (1992) P300-response: possible psychophysiological correlates in delta and theta frequency channels. A review. *Int J Psychophysiol* 13:161-179.
- Boekhoorn K, Joels M, Lucassen PJ (2006) Increased proliferation reflects glial and vascular-associated changes, but not neurogenesis in the presenile Alzheimer hippocampus. *Neurobiol Dis* 24:1-14.
- Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM (2007) Forecasting the global burden of Alzheimer's disease. *Alzheimers Dement* 3:186-191.
- Butterfield DA (2002) Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: Implications for neurodegeneration in Alzheimer's disease brain. A review. *Free Radical Res* 36:1307-1313.
- Chkhikvishvili I, Sanikidze T, Gogia N, McHedlishvili T, Enukidze M, Machavariani M, Vinokur Y, Rodov V (2013) Rosmarinic acid-rich extracts of summer savory (*Satureja hortensis* L.) protect Jurkat T cells against oxidative stress. *Oxidative medicine and cellular longevity* 2013:456253.
- Craig LA, Hong NS, McDonald RJ (2011) Revisiting the cholinergic hypothesis in the development of Alzheimer's disease. *Neuroscience and biobehavioral reviews* 35:1397-1409.
- Delbeuck X, Van der Linden M, Collette F (2003) Alzheimer's disease as a disconnection syndrome? *Neuropsychol Rev* 13:79-92.
- Ebert U, Kirch W (1998) Scopolamine model of dementia: electroencephalogram findings and cognitive performance. *European journal of clinical investigation* 28:944-949.
- El Omri A, Han JY, Yamada P, Kawada K, Ben Abdrabbah M, Isoda H (2010) Rosmarinus officinalis polyphenols activate cholinergic activities in PC12 cells through phosphorylation of ERK1/2. *J Ethnopharmacol* 131:451-458.
- Eriksson J, Villa AE (2005) Event-related potentials in an auditory oddball situation in the rat. *Biosystems* 79:207-212.
- Fallarini S, Miglio G, Paoletti T, Minassi A, Amoruso A, Bardelli C, Brunelleschi S, Lombardi G (2009) Clovamide and rosmarinic acid induce neuroprotective effects in in vitro models of neuronal death. *British journal of pharmacology* 157:1072-1084.

- 1
- 2
- 3
- 4 Filipcik P, Cente M, Ferencik M, Hulin I, Novak M (2006) The role of oxidative stress in the pathogenesis
- 5 of Alzheimer's disease. Bratislavske lekarske listy 107:384-394.
- 6 Garrido MI, Kilner JM, Kiebel SJ, Friston KJ (2009) Dynamic causal modeling of the response to
- 7 frequency deviants. Journal of neurophysiology 101:2620-2631.
- 8 Gates GA, Anderson ML, McCurry SM, Feeney MP, Larson EB (2011) Central Auditory Dysfunction as
- 9 a Harbinger of Alzheimer Dementia. Arch Otolaryngol 137:390-395.
- 10 Gok DK, Ozturk N, Er H, Aslan M, Demir N, Derin N, Agar A, Yargicoglu P (2015) Effects of rosmarinic
- 11 acid on cognitive and biochemical alterations in ovariectomized rats treated with D-galactose.
- 12 Folia Histochem Cyto 53:283-293.
- 13 Gsell W, Conrad R, Hickethier M, Sofic E, Frolich L, Wichart I, Jellinger K, Moll G, Ransmayr G,
- 14 Beckmann H, Riederer P (1995) Decreased Catalase Activity but Unchanged Superoxide-
- 15 Dismutase Activity in Brains of Patients with Dementia of Alzheimer-Type. J Neurochem
- 16 64:1216-1223.
- 17 Iliadou V, Kaprinis S (2003) Clinical psychoacoustics in Alzheimer's disease central auditory processing
- 18 disorders and speech deterioration. Annals of general hospital psychiatry 2:12.
- 19 Javitt DC, Schroeder CE, Steinschneider M, Arezzo JC, Vaughan HG, Jr. (1992) Demonstration of
- 20 mismatch negativity in the monkey. Electroencephalography and clinical neurophysiology 83:87-
- 21 90.
- 22 Javitt DC, Steinschneider M, Schroeder CE, Arezzo JC (1996) Role of cortical N-methyl-D-aspartate
- 23 receptors in auditory sensory memory and mismatch negativity generation: implications for
- 24 schizophrenia. Proc Natl Acad Sci U S A 93:11962-11967.
- 25 Jicha GA, Carr SA (2010) Conceptual evolution in Alzheimer's disease: implications for understanding
- 26 the clinical phenotype of progressive neurodegenerative disease. J Alzheimers Dis 19:253-272.
- 27 Kaminsky YG, Kosenko EA (2008) Effects of amyloid-beta peptides on hydrogen peroxide-metabolizing
- 28 enzymes in rat brain in vivo. Free Radic Res 42:564-573.
- 29 Kaser M, Soltesz F, Lawrence P, Miller S, Dodds C, Croft R, Dudas RB, Zaman R, Fernandez-Egea E,
- 30 Muller U, Dean A, Bullmore ET, Nathan PJ (2013) Oscillatory underpinnings of mismatch
- 31 negativity and their relationship with cognitive function in patients with schizophrenia. PloS one
- 32 8:e83255.
- 33 Kim HC, Yamada K, Nitta A, Olariu A, Tran MH, Mizuno M, Nakajima A, Nagai T, Kamei H, Jhoo WK,
- 34 Im DH, Shin EJ, Hjelle OP, Ottersen OP, Park SC, Kato K, Mirault ME, Nabeshima T (2003)
- 35 Immunocytochemical evidence that amyloid beta (1-42) impairs endogenous antioxidant systems
- 36 in vivo. Neuroscience 119:399-419.
- 37 Ko D, Kwon S, Lee GT, Im CH, Kim KH, Jung KY (2012) Theta oscillation related to the auditory
- 38 discrimination process in mismatch negativity: oddball versus control paradigm. J Clin Neurol
- 39 8:35-42.
- 40 LaFerla FM, Tinkle BT, Bieberich CJ, Haudenschield CC, Jay G (1995) The Alzheimer's A beta peptide
- 41 induces neurodegeneration and apoptotic cell death in transgenic mice. Nat Genet 9:21-30.
- 42 Lauderback CM, Hackett JM, Huang FF, Keller JN, Szweda LI, Markesbery WR, Butterfield DA (2001)
- 43 The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the
- 44 Alzheimer's disease brain: the role of A beta 1-42. J Neurochem 78:413-416.
- 45 Lazarewicz MT, Ehrlichman RS, Maxwell CR, Gandal MJ, Finkel LH, Siegel SJ (2010) Ketamine
- 46 modulates theta and gamma oscillations. Journal of cognitive neuroscience 22:1452-1464.
- 47 Leach ND, Nodal FR, Cordery PM, King AJ, Bajo VM (2013) Cortical Cholinergic Input Is Required for
- 48 Normal Auditory Perception and Experience-Dependent Plasticity in Adult Ferrets. J Neurosci
- 49 33:6659-6671.
- 50 Levanen S, Ahonen A, Hari R, McEvoy L, Sams M (1996) Deviant auditory stimuli activate human left
- 51 and right auditory cortex differently. Cerebral cortex 6:288-296.
- 52 Li J, Wang C, Zhang JH, Cai JM, Cao YP, Sun XJ (2010) Hydrogen-rich saline improves memory
- 53 function in a rat model of amyloid-beta-induced Alzheimer's disease by reduction of oxidative
- 54 stress. Brain Res 1328:152-161.
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65

- 1
- 2
- 3
- 4 Lovell MA, Ehmann WD, Butler SM, Markesbery WR (1995) Elevated Thiobarbituric Acid-Reactive
- 5 Substances and Antioxidant Enzyme-Activity in the Brain in Alzheimers-Disease. *Neurology*
- 6 45:1594-1601.
- 7
- 8 Lukatch HS, MacIver MB (1997) Physiology, pharmacology, and topography of cholinergic neocortical
- 9 oscillations in vitro. *Journal of neurophysiology* 77:2427-2445.
- 10
- 11 Makina T, Ono T, Liu N, Nakamura T, Muso E, Honda G (2002) Suppressive effects of Rosmarinic acid
- 12 on mesangioproliferative glomerulonephritis in rats. *Nephron* 92:898-904.
- 13
- 14 Marcus DL, Thomas C, Rodriguez C, Simberkoff K, Tsai JS, Strafaci JA, Freedman ML (1998) Increased
- 15 peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease. *Exp Neurol* 150:40-
- 16 44.
- 17
- 18 Medina D, DeToledo-Morrell L, Urresta F, Gabrieli JDE, Moseley M, Fleischman D, Bennett DA,
- 19 Leurgans S, Turner DA, Stebbins GT (2006) White matter changes in mild cognitive impairment
- 20 and AD: A diffusion tensor imaging study. *Neurobiol Aging* 27:663-672.
- 21
- 22 Mushtaq N, Schmatz R, Pereira LB, Ahmad M, Stefanello N, Vieira JM, Abdalla F, Rodrigues MV,
- 23 Baldissarelli J, Pelinson LP, Dalenogare DP, Reichert KP, Dutra EM, Mulinacci N, Innocenti M,
- 24 Bellumori M, Morsch VM, Schetinger MR (2014) Rosmarinic acid prevents lipid peroxidation
- 25 and increase in acetylcholinesterase activity in brain of streptozotocin-induced diabetic rats. *Cell*
- 26 *Biochem Funct* 32:287-293.
- 27
- 28 Naatanen R, Gaillard AW, Mantysalo S (1978) Early selective-attention effect on evoked potential
- 29 reinterpreted. *Acta psychologica* 42:313-329.
- 30
- 31 Naatanen R, Lehtokoski A, Lennes M, Cheour M, Huottilainen M, Iivonen A, Vainio M, Alku P,
- 32 Ilmoniemi RJ, Luuk A, Allik J, Sinkkonen J, Alho K (1997) Language-specific phoneme
- 33 representations revealed by electric and magnetic brain responses. *Nature* 385:432-434.
- 34
- 35 Naggara O, Oppenheim C, Rieu D, Raoux N, Rodrigo S, Dalla Barba G, Meder JF (2006) Diffusion tensor
- 36 imaging in early Alzheimer's disease. *Psychiat Res-Neuroim* 146:243-249.
- 37
- 38 Nakamura T, Michie PT, Fulham WR, Todd J, Budd TW, Schall U, Hunter M, Hodgson DM (2011)
- 39 Epidural Auditory Event-Related Potentials in the Rat to Frequency and duration Deviants:
- 40 Evidence of Mismatch Negativity? *Frontiers in psychology* 2:367.
- 41
- 42 Ono K, Li L, Takamura Y, Yoshiike Y, Zhu LJ, Han F, Mao X, Ikeda T, Takasaki J, Nishijo H,
- 43 Takashima A, Teplow DB, Zagorski MG, Yamada M (2012) Phenolic Compounds Prevent
- 44 Amyloid beta-Protein Oligomerization and Synaptic Dysfunction by Site-specific Binding.
- 45 *Journal of Biological Chemistry* 287:14631-14643.
- 46
- 47 Padurariu M, Ciobica A, Hritcu L, Stoica B, Bild W, Stefanescu C (2010) Changes of some oxidative
- 48 stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease.
- 49 *Neurosci Lett* 469:6-10.
- 50
- 51 Palop JJ, Mucke L (2010) Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from
- 52 synapses toward neural networks. *Nat Neurosci* 13:812-818.
- 53
- 54 Parihar MS, Hemnani T (2004) Alzheimer's disease pathogenesis and therapeutic interventions. *Journal of*
- 55 *clinical neuroscience : official journal of the Neurosurgical Society of Australasia* 11:456-467.
- 56
- 57 Pearson RC, Sofroniew MV, Powell TP (1984) Hypertrophy of immunohistochemically identified
- 58 cholinergic neurons of the basal nucleus of Meynert following ablation of the contralateral cortex
- 59 in the rat. *Brain Res* 311:194-198.
- 60
- 61 Pekkonen E, Hirvonen J, Jaaskelainen IP, Kaakkola S, Huttunen J (2001) Auditory sensory memory and
- 62 the cholinergic system: implications for Alzheimer's disease. *Neuroimage* 14:376-382.
- 63
- 64 Pepeu G, Giovannelli L, Casamenti F, Scali C, Bartolini L (1996) Amyloid beta-peptides injection into the
- 65 cholinergic nuclei: Morphological, neurochemical and behavioral effects. *Cholinergic*
- Mechanisms: From Molecular Biology to Clinical Significance* 109:273-282.
- Perry EK, Tomlinson BE, Blessed G, Perry RH, Cross AJ, Crow TT (1981) Noradrenergic and cholinergic
- systems in senile dementia of Alzheimer type. *Lancet* 2:149.
- Picciotto MR, Higley MJ, Mineur YS (2012) Acetylcholine as a Neuromodulator: Cholinergic Signaling
- Shapes Nervous System Function and Behavior. *Neuron* 76:116-129.

- 1
- 2
- 3
- 4 Puertas MC, Martinez-Martos JM, Cobo MP, Carrera MP, Mayas MD, Ramirez-Exposito MJ (2012)
- 5 Plasma oxidative stress parameters in men and women with early stage Alzheimer type dementia.
- 6 Experimental gerontology 47:625-630.
- 7
- 8 Rodriguez R, Kallenbach U, Singer W, Munk MH (2004) Short- and long-term effects of cholinergic
- 9 modulation on gamma oscillations and response synchronization in the visual cortex. J Neurosci
- 10 24:10369-10378.
- 11 Ruusuvirta T, Penttonen M, Korhonen T (1998) Auditory cortical event-related potentials to pitch
- 12 deviances in rats. Neurosci Lett 248:45-48.
- 13 Sarter M, Hasselmo ME, Bruno JP, Givens B (2005) Unraveling the attentional functions of cortical
- 14 cholinergic inputs: interactions between signal-driven and cognitive modulation of signal
- 15 detection. Brain Res Rev 48:98-111.
- 16 Soobrattee MA, Neergheen VS, Luximon-Ramma A, Aruoma OI, Bahorun T (2005) Phenolics as
- 17 potential antioxidant therapeutic agents: mechanism and actions. Mutation research 579:200-213.
- 18 Soodi M, Naghdi N, Hajimehdipour H, Choopani S, Sahraei E (2014) Memory-improving activity of
- 19 Melissa officinalis extract in naive and scopolamine-treated rats. Research in pharmaceutical
- 20 sciences 9:107-114.
- 21
- 22 Sultana R, Piroddi M, Galli F, Butterfield DA (2008) Protein Levels and Activity of Some Antioxidant
- 23 Enzymes in Hippocampus of Subjects with Amnesic Mild Cognitive Impairment. Neurochem
- 24 Res 33:2540-2546.
- 25 Tervaniemi M, Medvedev SV, Alho K, Pakhomov SV, Roudas MS, Van Zuijen TL, Naatanen R (2000)
- 26 Lateralized automatic auditory processing of phonetic versus musical information: a PET study.
- 27 Human brain mapping 10:74-79.
- 28
- 29 Tran MH, Yamada K, Nabeshima T (2002) Amyloid beta-peptide induces cholinergic dysfunction and
- 30 cognitive deficits: a minireview. Peptides 23:1271-1283.
- 31 van Wingerden M, Vinck M, Tijms V, Ferreira IR, Jonker AJ, Pennartz CM (2012) NMDA receptors
- 32 control cue-outcome selectivity and plasticity of orbitofrontal firing patterns during associative
- 33 stimulus-reward learning. Neuron 76:813-825.
- 34 Vladimir-Knezevic S, Blazekovic B, Kindl M, Vladic J, Lower-Nedza AD, Brantner AH (2014)
- 35 Acetylcholinesterase inhibitory, antioxidant and phytochemical properties of selected medicinal
- 36 plants of the Lamiaceae family. Molecules 19:767-782.
- 37 Wasowicz W, Neve J, Peretz A (1993) Optimized steps in fluorometric determination of thiobarbituric
- 38 acid-reactive substances in serum: importance of extraction pH and influence of sample
- 39 preservation and storage. Clinical chemistry 39:2522-2526.
- 40
- 41 Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR (1982) Alzheimer's disease and
- 42 senile dementia: loss of neurons in the basal forebrain. Science 215:1237-1239.
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65

Figure 1
[Click here to download high resolution image](#)

Figure 2
[Click here to download high resolution image](#)

Figure 3
[Click here to download high resolution image](#)

Figure 4
[Click here to download high resolution image](#)

Bottom panel

Figure 5
[Click here to download high resolution image](#)

Tables

Table 1. The mean and standard errors of peak latencies of ERP components in response to Standard and the deviant tones for 375 ms ISI value in all experimental groups.

		P1N1		N1P2		P2N2	
	Groups	StbD	Dev	StbD	Dev	StbD	Dev
F_{right}	S	6,70 ± 0,76	5,36 ±0,39	7,14±0,45	7,07±0, 62	5,81±0,94	6,69±0,44
	SR	4,30 ± 0,48	4,96±0,50	6,99±0,58	4,63±0,55	4,22±0,48	5,66±0,35
	Aβ	4,83 ± 0,46	4,07±0,20	7,83±0,76	4,67±0,42	5,66±0,34	5,48±0,58
	AβR	4,80 ±0,57	4,46±0,62	7,40±0,39	4,39±0,46	5,51±0,60	5,78±0,39
F_{Left}	S	5,78±0,66	6,99±0,40	11,17±0,64	6,58±0,59 ψ	6,37±0,41	12,33±0,55 ψ
	SR	4,97±0,52	5,42±0,32	10,07±0,47	4,90±0,53 ψ	5,23±0,37	11,07±0,63 ψ
	Aβ	4,97±0,14	5,04±0,30	9,21±0,62	5,55±0,25 ψ	5,54±0,36	10,92±0,76 ψ
	AβR	4,45±0,52	4,64±0,45	10,33±0,32	4,67±0,54 ψ	5,46±0,59	10,35±0,36 ψ
AC_{right}	S	6,38±0,58	6,40±0,48	12,31±0,63	5,28±0,36 ψ	6,77±0,51	12,06±0,82 ψ
	SR	6,30±0,34	5,83±0,53	10,72±0,68	6,36±0,55 ψ	6,05±0,25	11,89±0,53 ψ
	Aβ	5,47±0,42	4,32±0,39	8,81±0,33	5,13±0,29 ψ	5,15±0,41	10,60±0,37 ψ
	AβR	5,34±0,44	5,78±0,52	9,34±0,51	5,38±0,25 ψ	5,17±0,27	9,51±0,70 ψ
AC_{Left}	S	5,20±0,37	5,99±0,48	12,75±0,64	5,76±0,25 ψ	6,36±0,33	13,03±0,60 ψ
	SR	5,90±0,41	5,85±0,61	11,51±0,61	5,10±0,46 ψ	5,93±0,34	10,63±0,26 ψ
	Aβ	6,40±0,59	6,30±0,59	11,07±0,60	5,04±0,37 ψ	5,60±0,19	11,55±0,63 ψ
	AβR	4,78±0,34	4,80±0,30	10,68±0,71	5,13±0,58 ψ	6,04±0,31	11,23±0,53 ψ

ψ : Significant difference in within group comparisons

Table 2. The mean and standard errors of peak latencies of AERP components in response to Standard and the deviant tones for 600 ms ISI value in all experimental groups.

		P1N1		N1P2		P2N2	
		StbD	Dev	StbD	Dev	StbD	Dev
F_{right}	S	5,23±0,58	5,36±0,29	7,28±0,60	5,80±0,23	5,91±0,25	5,21±0,19
	SR	4,37±0,14	4,87±0,33	8,51±0,25	6,07±0,16	5,61±0,32	5,71±0,24
	Aβ	4,86±0,59	6,66±0,43	7,25±0,65	5,04±0,33	6,07±0,67	5,97±0,45
	AβR	6,01±0,51	6,06±0,29	7,93±0,37	6,22±0,43	6,33±0,59	6,58±0,57
F_{left}	S	5,11±0,61	5,23±0,66	10,85±0,44	6,66±0,63 ψ	6,85±0,32	13,01±0,67 ψ
	SR	5,46±0,42	5,37±0,69	12,05±1,17	6,44±0,60 ψ	5,56±0,21	10,70±0,41 ψ
	Aβ	5,91±0,62	6,93±0,55	10,10±0,24	9,78±0,50 *	5,96±0,40	7,99±0,40 *
	AβR	6,43±0,37	6,41±0,47	11,17±0,59	7,01±0,51 ψ ξ	6,48±0,52	12,51±0,81 ψ ξ
AC_{right}	S	4,79±0,41	6,77±0,59	9,78±0,45	4,69±0,49 ψ	5,96±0,52	11,83±0,26 ψ
	SR	5,58±0,55	6,96±0,29	11,27±0,63	5,49±0,19 ψ	6,71±0,42	13,58±0,54 ψ
	Aβ	6,75±0,82	7,39±0,53	9,94±0,23	9,28±0,45 *	6,59±1,11	8,06±0,54 *
	AβR	6,70±0,45	6,02±0,41	10,48±0,47 ξ	5,56±0,28 ψ ξ	5,50±0,42	11,10±0,94 ψ ξ
AC_{left}	S	6,28±0,19	6,74±0,35	11,04±0,47	5,91±0,39 ψ	6,10±0,43	13,05±0,67 ψ
	SR	5,08±0,24	5,35±0,32	11,11±0,50	5,73±0,28 ψ	5,33±0,33	10,25±0,39 ψ
	Aβ	6,31±0,50	6,51±0,89	9,26±0,20	9,06±0,24 *	6,30±0,26	8,50±0,43 *
	AβR	6,33±0,21	6,12±0,39	10,50±0,68	6,01±0,64 ψ ξ	6,48±0,20	11,36±0,35 ψ ξ

ψ : Significant difference in within group comparisons

* : Significant difference versus sham group

ξ : Significant difference versus Aβ group

Tablo 3. The mean and standard errors of theta power values of AERPs in response to standard and the deviant tones for 375 and 600 ms ISI values in all experimental groups.

Theta power (μV^2)					
		ISI 375		ISI 600	
		StbD	Dev	StbD	Dev
Fright	S	5,70± 1,09	6,55± 2,45	4,40± 0,41	5,07± 0,47
	SR	5,64± 2,39	6,54± 1,05	4,70± 0,98	5,24± 0,81
	Aβ	6,00± 0,90	5,02± 0,49	3,90± 0,88	5,28± 1,55
	AβR	7,38± 1,92	6,08± 0,35	6,68± 0,67	7,32± 1,77
Fleft	S	6,69± 0,57	12,83± 1,12 Ψ	4,57± 0,50	9,27± 0,32 Ψ
	SR	6,74± 0,71	11,42± 0,65 Ψ	4,18± 0,39	9,14± 0,27 Ψ
	Aβ	6,14± 0,57	9,89± 0,28 Ψ	5,84± 0,46	5,40± 1,33 *
	AβR	6,96± 0,45	9,62± 0,68 Ψ	5,46± 0,48	12,10± 1,02 Ψ ξ
ACright	S	7,89± 0,51	10,95± 0,59 Ψ	4,90± 0,69	9,55± 0,39 Ψ
	SR	7,30± 0,57	12,70± 0,56 Ψ	5,16± 0,42	10,05± 0,42 Ψ
	Aβ	6,54± 0,90	9,22± 0,96 Ψ	6,62± 0,93	5,32± 0,66 *
	AβR	7,76± 0,32	12,52± 0,86 Ψ	6,80± 0,46	11,52± 0,69 Ψ ξ
ACleft	S	7,14± 0,61	12,09± 0,68 Ψ	4,69± 0,46	9,90± 0,47
	SR	8,84± 0,51	13,78± 0,38 Ψ	6,48± 0,58	10,40± 0,56 Ψ
	Aβ	7,54± 0,49	12,08± 0,73 Ψ	5,96± 1,03	5,92± 0,35 *
	AβR	8,28± 0,38	12,70± 0,59 Ψ	5,74± 0,39	11,24± 0,41 Ψ ξ

Ψ : Significant difference in within group comparisons

* : Significant difference versus sham group

ξ : Significant difference versus A β group

Table 4. The mean and standard errors of theta coherence values of AERPs in response to StbD and Dev tones for 375 and 600 ms ISI values in all experimental groups.

		$F_{\text{right}} - F_{\text{left}}$	$AC_{\text{right}} - AC_{\text{left}}$	$F_{\text{right}} - AC_{\text{right}}$	$F_{\text{right}} - AC_{\text{left}}$	$F_{\text{left}} - AC_{\text{right}}$	$F_{\text{left}} - AC_{\text{left}}$
ISI375 StbD	S	0,766± 0,028	0,618± 0,029	0,111± 0,013	0,085± 0,009	0,090± 0,008	0,084± 0,007
	SR	0,773± 0,023	0,616± 0,021	0,299± 0,098	0,125± 0,017	0,165± 0,026	0,150± 0,035
	Aβ	0,754± 0,021	0,624± 0,035	0,174± 0,022	0,118± 0,010	0,229± 0,017	0,166± 0,013
	AβR	0,746± 0,049	0,528± 0,043	0,194± 0,043	0,200± 0,010	0,240± 0,080	0,171± 0,017
ISI375 Dev	S	0,760± 0,015	0,596± 0,017	0,194± 0,029	0,132± 0,009	0,181± 0,023	0,143± 0,012
	SR	0,808± 0,033	0,616± 0,021	0,169± 0,020	0,180± 0,012	0,154± 0,015	0,166± 0,016
	Aβ	0,776± 0,022	0,318± 0,026 *	0,115± 0,026	0,170± 0,033	0,114± 0,010	0,171± 0,049
	AβR	0,684± 0,032	0,645± 0,021 ξ	0,164± 0,017	0,148± 0,017	0,230± 0,019	0,205± 0,013
ISI600 StbD	S	0,790± 0,042	0,646± 0,024	0,249± 0,104	0,151± 0,022	0,239± 0,082	0,190± 0,025
	SR	0,764± 0,018	0,556± 0,027	0,174± 0,028	0,162± 0,011	0,184± 0,023	0,183± 0,014
	Aβ	0,786± 0,030	0,624± 0,028	0,143± 0,042	0,103± 0,014	0,103± 0,021	0,141± 0,031
	AβR	0,808± 0,025	0,669± 0,029	0,168± 0,033	0,115± 0,015	0,111± 0,013	0,168± 0,028
ISI600 Dev	S	0,815± 0,023	0,701± 0,025	0,278± 0,052	0,130± 0,009	0,251± 0,045	0,218± 0,031
	SR	0,828± 0,021	0,713± 0,037	0,405± 0,096	0,413± 0,073	0,358± 0,066	0,304± 0,084
	Aβ	0,809± 0,012	0,292± 0,015 *	0,248± 0,034	0,190± 0,029	0,206± 0,027	0,207± 0,026
	AβR	0,813± 0,021	0,630± 0,027 ξ	0,134± 0,014	0,080± 0,030	0,080± 0,017	0,085± 0,026

* : Significant difference versus sham group

ξ : Significant difference versus Aβ group